ArticlePlant cell reports2026
Marigold suspension cell culture as production system for recombinant DsRed and brazzein.
Article in Plant cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
key messageNewly established Calendula officinalis suspension culture with low protease activity in the supernatant is transformed and produces high yields of recombinant proteins both in the cytosol and in the apoplast. A marigold (Calendula officinalis) suspension cell culture (CR1) was established from very young root tissues. Protease activity was checked in the cell culture supernatant (SN) and was found to be very low. To determine if CR1 could be a suitable production platform for recombinant proteins, a transformation was performed. Using Agrobacterium tumefaciens, CR1 was transformed with a construct containing two cassettes: one coding for a red fluorescent protein (DsRed) targeted to the endoplasmic reticulum and the other coding for the sweet protein brazzein, targeted to the apoplast. Suspension cultures were initiated from calli that exhibited strong DsRed fluorescence. A brazzein standard was prepared from the SN of one transformed CR1 line by purifying brazzein and subsequent quantification via tryptic digest and mass spectrometric comparison with a commercial brazzein-derived peptide of known concentration. This standard was used to determine the brazzein concentration in seven different transgenic CR1 transformation events by liquid chromatography-tandem mass spectrometry (LC-MS/MS), with the highest concentration measured at 24.5 µg/ml. Quantification of DsRed production in the cells of the same cultures showed up to 1322 µg/g fresh weight of DsRed (equivalent to 34.9% of total soluble protein). CR1 is potentially an excellent novel alternative to BY2 cells for the production of recombinant proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.